Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia

• ClinicalTrials.gov Identifier: NCT05611593
• Recruitment Status: Recruiting
• First Posted: November 10, 2022
• Last Update Posted: November 10, 2022
• Sponsor: Follicle Pharma Ltd
• Information provided by (Responsible Party): Follicle Pharma Ltd

Study Description

Brief Summary:

The CSP-001-FOL1 clinical study is aimed to investigate whether local topical administration of FOL100 lotion will be safe for the patient and will not cause local or systemic skin or other adverse events. It is also aimed at indicating effectiveness as compared with oral Finasteride 1mg. In this non-blinded study, each patient will choose his preferred arm (oral finasteride or FOL100 location). During the study, safety and efficacy will be measured as well as usability.

Condition or disease	Intervention/treatment	Phase
Androgenic Alopecia	Drug: FOL100; Drug: Propecia 1Mg Tablet	Phase 1

Detailed Description:

The proposed clinical study aims to test the safety, tolerability and usability of FOL100 compared to the commercially available Finasteride 1mg Propecia in male subjects suffering from AA.

Study endpoints:

Primary Endpoint:

Safety-AE(s) & SAE(s) incidence rate. Secondary Endpoint: Tolerability & usability collecting information on safety, tolerability & usability.

Exploratory Endpoint: Efficacy

1. Mean change in total, vellus and non-vellus hair count, total hair density, cumulative hair diameter and mean hair thickness in the target region.
2. Global photographic assessments.
3. Subject self-assessment.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 66 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Parallel Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase-I, Open Label, Multi-Centre Clinical Study to Assess the Safety, Tolerability and Usability of FOL100 Lotion in Comparison to Oral Finasteride, for the Treatment of Androgenetic Alopecia
• Actual Study Start Date: October 20, 2022
• Estimated Primary Completion Date: December 2024
• Estimated Study Completion Date: February 2025

Arms and Interventions

Arm	Intervention/treatment
Experimental: FOL100; Subjects will apply FOL100 lotion topically in the defined treatment area.	Drug: FOL100; FOL100 lotion
Active Comparator: Propecia 1mg (oral Finasteride); Participants will receive1 tablet of Propecia 1mg (oral Finasteride) once daily (q.d)	Drug: Propecia 1Mg Tablet; Oral Finasteride; Other Name: Oral Finasteride

Outcome Measures

Primary Outcome Measures :

1. Safety [ Time Frame: 28 weeks ]
   Adverse event reporting (local and general)

Secondary Outcome Measures :

1. Tolerability & Usability [ Time Frame: 28 weeks ]
   Subject self-assessment by questionnaire

Other Outcome Measures:

1. Change in hair count [ Time Frame: 28 weeks ]
   Change in total hair count, vellus and non-vellus hair count per cm^2 as assessed by Phototrichogram
2. Change in total hair density [ Time Frame: 28 weeks ]
   Change in total hair density per cm^2 as assessed by Phototrichogram
3. Change in hair thickness [ Time Frame: 28 weeks ]
   Change in cumulative diameter and hair thickness per cm^2 as assessed by Phototrichogram
4. Exploratory Endpoint: Efficacy - self-assess [ Time Frame: 28 weeks ]
   Subject self-assessment by questionnaire

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 40 Years (Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Written informed consent will be signed by the subject before starting any study related procedures.
2. Male subject between the ages of 18 to 40 years old.
3. Male subject with mild to moderate vertex male-pattern hair loss, classified as grade III vertex and IV, according to the modified Norwood/Hamilton Scale.
4. Subject must be willing to maintain normal shampooing habits and products during the study.
5. Fitzpatrick skin phototype classification of I-IV.
6. Subjects will agree to maintain the same haircut and color throughout the study, with no significant changes that will interfere with study objectives, as determined by the investigator.
7. Ability to understand and cooperate with the investigator and to comply with the requirements of the study protocol.

Exclusion Criteria:

1. Clinically significant abnormal skin findings on the scalp, which in the opinion of the investigator, could interfere with the aim of the study; in particular, abrasion, actinic keratosis, inflammatory disorders, or any other abnormality.
2. Hair transplant surgery or hair weaving.
3. Clinically significant and active physical illness that could interfere with study objectives or may risk patient safety as determined by the Investigator during screening.
4. Ascertained or presumptive hypersensitivity to the active principle and/or any of the formulation ingredients; history of anaphylaxis to drugs or allergic reactions in general, which in the opinion of the investigator may affect subject safety or the outcome of the study.
5. History of local infections of the skin or subcutaneous tissues of the head within 3 months prior to study enrollment.
6. Clinically significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, hematological, endocrine, or neurological diseases, which in the opinion of the investigator may affect subject safety or the outcome of the study.
7. Suspicion of malignancy, including prostate cancer.
8. Subject whose sexual partner(s) is pregnant or plan to become pregnant.
9. Concurrent use of systemic corticosteroids, topical corticosteroids in the area treated in the study, anabolic steroids, or over the counter "hair restorers".

10. Use of any of the following products in the past year that may affect hair growth:

    minoxidil (topical or oral), zidovudine, cyclosporine, diazoxide, phenytoin, systemic interferon, psoralens, streptomycin, penicillamine ,benoxaprofen, tamoxifen, phenothiazines or cytotoxic agents.

11. Use of oral finasteride or dutasteride, within 18 months prior to enrollment and 12 months prior to enrollment for any topical medication that is considered to affect hair growth.
12. Use of a therapeutic shampoo administered by a physician with prescription within 1 month prior to enrollment.
13. Light or laser treatment of scalp within 3 months prior to enrollment.
14. Unwilling to undergo a superficial ink marking on the scalp vertex during V0.

Contacts and Locations

Contacts

Contact: Solli Brawer; +972747366444; info@folliclepharma.com

Contact: Offer Fabian; +972747366444; info@folliclepharma.com

Locations

Israel

Rabin Medical Center; Recruiting

Petah tikva, Israel

Contact: Helena Martinez, MD

Sheba Medical Center; Recruiting

Ramat Gan, Israel

Contact: Anna Lyakhovitsky, MD

Sourasky Medical Center; Recruiting

Tel Aviv, Israel

Contact: Amir Koren

Sponsors and Collaborators

Follicle Pharma Ltd

Investigators

• Study Director: Solli Brawer; Follicle Pharma Ltd

More Information

• Responsible Party: Follicle Pharma Ltd
• ClinicalTrials.gov Identifier: NCT05611593
• Other Study ID Numbers: CSP-001-FOL1
• First Posted: November 10, 2022
• Last Update Posted: November 10, 2022
• Last Verified: November 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Alopecia; Alopecia Areata; Hypotrichosis; Hair Diseases; Skin Diseases; Pathological Conditions, Anatomical; Finasteride; 5-alpha Reductase Inhibitors; Steroid Synthesis Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; Urological Agents